Caris Life Sciences is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve cancer patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Caris' latest advancement is a blood-based, cNAS assay that combines comprehensive molecular analysis and serial monitoring - making it the most powerful liquid biopsy assay ever developed.